Daiichi Sankyo
4568.TPharmaceutical
Financials · Standalone
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥1.81T | ¥1.36T | ¥1.21T | ¥859.0bn | ¥754.0bn | ¥701.0bn |
| Operating income | ¥469.4bnr | ¥159.1bn | ¥104.1bn | −¥37.1bn | ¥10.2bn | ¥39.7bn |
| Ordinary income | ¥548.1bnr | ¥202.0bnr | ¥182.7bn | ¥91.6bn | ¥47.7bn | ¥84.5bn |
| Total assets | ¥3.38Tr | ¥2.70T | ¥2.56T | ¥1.87T | ¥1.64T | ¥1.59T |
| Net assets / equity | ¥1.13Tr | ¥938.7bn | ¥1.10T | ¥977.6bn | ¥930.3bn | ¥947.8bn |
| EPS (basic) | ¥252.78r | ¥105.85 | ¥96.03 | ¥54.38 | ¥20.49 | ¥41.77 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | AnnualAmended | 211 figures · EDINET |
| 2025-04-01 → 2026-03-31 | AnnualAmended | 211 figures · EDINET |
| 2025-04-01 → 2026-03-31 | Annual | 211 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 80 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 213 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 80 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 213 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 106 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 211 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 102 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 102 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 80 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 213 figures · EDINET |
22 more reports are still being processed.